<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007106</url>
  </required_header>
  <id_info>
    <org_study_id>7684A-005</org_study_id>
    <secondary_id>2021-001009-56</secondary_id>
    <secondary_id>MK-7684A-005</secondary_id>
    <secondary_id>jRCT2031210335</secondary_id>
    <nct_id>NCT05007106</nct_id>
  </id_info>
  <brief_title>MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)</brief_title>
  <official_title>A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and preliminary efficacy&#xD;
      of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer&#xD;
      therapies in participants with selected advanced solid tumors. The primary hypothesis is that&#xD;
      pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of&#xD;
      objective response rate or progression-free survival in participants with cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">February 19, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants with locally recurrent unresectable or metastatic cervical cancer whose tumors express programmed cell death 1 ligand 1 (PD-LI) and have a combined positive score (CPS) ≥1 will be randomly assigned to treatment with either pembrolizumab/vibostolimab co-formulation or pembrolizumab only. The other study intervention arms will be assigned to participants depending on the selected cancer type.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR per RECIST 1.1 as Assessed by Investigator</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS per RECIST 1.1 as Assessed by Investigator</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by investigator will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per RECIST 1.1 as Assessed by Investigator</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by investigator will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30)</measure>
    <time_frame>Baseline and up to approximately 36 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5)</measure>
    <time_frame>Baseline and up to approximately 36 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Intervention Due to an AE</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Endometrial Neoplasms</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Gallbladder Neoplasms</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Esophageal Neoplasms</condition>
  <condition>Triple Negative Breast Neoplasms</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. After completion of initial treatment, participants may be eligible for second course treatment with pembrolizumab/vibostolimab for up to 17 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles. After completion of initial treatment, participants may be eligible for second course treatment with pembrolizumab for up to 17 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) until meeting discontinuation criteria. Participants may receive second course of pembrolizumab/vibostolimab plus lenvatinib at the the discretion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW &lt;60 kg) qd until meeting discontinuation criteria. Participants may receive second course of pembrolizumab/vibostolimab plus lenvatinib at the the discretion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU) 800 mg/m^2/day via IV infusion Q3W, plus Cisplatin 80 mg/m^2 via IV infusion Q3W. Participants may receive second course of pembrolizumab/vibostolimab plus chemotherapy at the the discretion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel 90 mg/m^2 on days 1, 8, and 15 of every 28-day treatment cycle until meeting discontinuation criteria. Participants may receive second course of pembrolizumab/vibostolimab plus paclitaxel at the the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab/Vibostolimab Co-Formulation</intervention_name>
    <description>Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W</description>
    <arm_group_label>Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin</arm_group_label>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation</arm_group_label>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)</arm_group_label>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)</arm_group_label>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel</arm_group_label>
    <other_name>MK-7684A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg administered via IV infusion Q3W.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD</description>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)</arm_group_label>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)</arm_group_label>
    <other_name>Lenvima</other_name>
    <other_name>E7080</other_name>
    <other_name>MK-7902</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles</description>
    <arm_group_label>Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Fluracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80 mg/m^2 administered via IV infusion Q3W up to 6 cycles</description>
    <arm_group_label>Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>cis Platinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 90 mg/m^2 administered via IV infusion on days 1, 8, and 15 of every 28-day treatment cycle</description>
    <arm_group_label>Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Anzatax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  One of the following histologically or cytologically confirmed, advanced (locally&#xD;
             recurrent unresectable or metastatic) solid tumors:&#xD;
&#xD;
               -  Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix&#xD;
&#xD;
               -  Endometrial cancer&#xD;
&#xD;
               -  Head and neck swuamous cell carcinoma (HNSCC)&#xD;
&#xD;
               -  Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or&#xD;
                  extrahepatic] cholangiocarcinoma)&#xD;
&#xD;
               -  Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic&#xD;
                  Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).&#xD;
&#xD;
               -  Triple-negative breast cancer (TNBC)&#xD;
&#xD;
               -  Hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.&#xD;
&#xD;
          -  Adequately controlled blood pressure (BP) with or without antihypertensive&#xD;
             medications.&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV&#xD;
             on anti-retroviral therapy (ART).&#xD;
&#xD;
          -  Male participants must agree to follow contraceptive guidance.&#xD;
&#xD;
          -  Female participants are not pregnant or breastfeeding, not a woman of child-bearing&#xD;
             potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of a second malignancy, unless potentially curative treatment has been&#xD;
             completed with no evidence of malignancy for 3 years.&#xD;
&#xD;
          -  Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or&#xD;
             anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.&#xD;
&#xD;
          -  Prior systemic anticancer therapy including investigational agents within 4 weeks&#xD;
             before randomization/allocation.&#xD;
&#xD;
          -  Received a live or live-attenuated vaccine within 30 days before the first dose of&#xD;
             study intervention. Administration of killed vaccines are allowed.&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days before the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in past 2 years.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Concurrent active Hepatitis B and Hepatitis C virus infection.&#xD;
&#xD;
          -  History of allogenic tissue/solid organ transplant.&#xD;
&#xD;
          -  Previous treatment with lenvatinib (for participants who will receive lenvatinib in&#xD;
             their assigned treatment arm).&#xD;
&#xD;
          -  History of congestive heart failure or myocardial infarction within 6 months of&#xD;
             treatment (for participants who will receive paclitaxel in their assigned allocation&#xD;
             arm).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center ( Site 1001)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>888-88-8888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Lind Centro de Investigación del Cáncer ( Site 1404)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4780000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56961064692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FALP-UIDO ( Site 1401)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56939263055</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncovida ( Site 1405)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7510032</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56961064692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradfordhill-Clinical Area ( Site 1402)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56961064692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Oncology ( Site 1141)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+ 972 4 7776724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center-Oncology ( Site 1142)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+ 972 2 6776760</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center-Oncology ( Site 1143)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+ 972 3 6973082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 1321)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-4-7133-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 1322)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3542-2511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital-Internal Medicine ( Site 1312)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-2072-0850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-2228-8132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48 22 546 33 81</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48502204953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)</name>
      <address>
        <city>Hospitalet</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>932607294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34914521987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955013068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886-6-2353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital-Oncology ( Site 1301)</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886-2-23123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital ( Site 1305)</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886 2 2543 3535</phone>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

